Spontaneous reporting of adverse reactions associated with the COVID-19 vaccine in health care professionals: A descriptive observational study conducted in a Portuguese hospital
暂无分享,去创建一个
P. Matos | Paulo Pinho | Nuno A. Saldanha | A. Dias | Vanessa S. G. Teófilo | Gonçalo J. Cordeiro | Rui A. M. Ribeiro | Salomé M. Moreira | Mariana S. F Miller | Marta F. R. Couto | Pedro M. P. N. S. Norton
[1] Ojbindra Kc,et al. A Rare Case of Longitudinally Extensive Transverse Myelitis Following Pfizer-BioNTech COVID-19 Vaccination with a Favourable Outcome , 2022, European journal of case reports in internal medicine.
[2] T. Nieminen,et al. Sudden hearing loss following vaccination against COVID-19 , 2022, medRxiv.
[3] S. Anvari,et al. Hypersensitivity Reactions to COVID-19 Vaccines-Identify High-Risk Children and Vaccinate the Rest. , 2022, JAMA pediatrics.
[4] T. Sawa,et al. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers , 2022, Journal of Infection and Chemotherapy.
[5] J. Guarnaccia,et al. Transverse myelitis as a first event of multiple sclerosis precipitated by Pfizer-BioNTech COVID-19 vaccination , 2022, Neuroimmunology Reports.
[6] N. Randhawa,et al. Incomplete Subacute Transverse Myelitis Following Vaccination With Pfizer-BioNTech COVID-19 mRNA Vaccine: A Case Report , 2021, Cureus.
[7] J. Olgin,et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination , 2021, JAMA network open.
[8] J. Al-Tawfiq,et al. Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia , 2021, Preventive medicine reports.
[9] Ahmed N. Alghamdi,et al. BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees , 2021, Frontiers in Medicine.
[10] A. Shrestha,et al. Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature , 2021, Journal of Neurology.
[11] Yan Yan,et al. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan , 2021, Journal of Infection and Chemotherapy.
[12] M. Klugar,et al. Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia , 2021, Pharmaceuticals.
[13] A. Rodríguez-Morales,et al. Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems , 2021, Drugs & Therapy Perspectives.
[14] M. Mekhemar,et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers , 2021, Biology.
[15] N. Realdon,et al. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 , 2021, European journal of hospital pharmacy : science and practice.
[16] S. Ladhani,et al. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[17] Joon Seo Lim,et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea , 2021, Journal of Korean medical science.
[18] J. Gee,et al. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. , 2021, JAMA.
[19] B. Alghamdi,et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study , 2021, International journal of general medicine.
[20] Sameh Attia,et al. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic , 2021, Journal of clinical medicine.
[21] M. Sotir,et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[22] WHO ISSUES ITS FIRST EMERGENCY USE VALIDATION FOR A COVID-19 VACCINE AND EMPHASIZES NEED FOR EQUITABLE GLOBAL ACCESS , 2021, Saudi Medical Journal.
[23] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[24] A. Rodríguez-Morales,et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic , 2020, Annals of clinical microbiology and antimicrobials.
[25] V. Paudyal,et al. Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis , 2020, Expert opinion on drug safety.
[26] R. Williams,et al. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation , 2020, AAPS PharmSciTech.
[27] A. Rodríguez-Morales,et al. A vaccine is not too far for COVID-19. , 2020, Journal of infection in developing countries.
[28] Subish Palaian,et al. Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal , 2020, Therapeutic advances in drug safety.
[29] Qianyun Liu,et al. Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.
[30] X. Mariette,et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. , 2013, Rheumatology.